Eli Lilly reported positive phase III data for retatrutide, a triple‑agonist targeting GLP‑1, GIP and glucagon receptors, showing robust A1C reductions and substantial weight loss in patients with type 2 diabetes. Top‑line results from Transcend‑T2D‑1 demonstrated clinically meaningful glycemic control and placebo‑adjusted weight losses, with the highest doses delivering the largest effects. Company statements and trial summaries indicate the regimen met primary and key secondary endpoints over 40 weeks; safety signals (nausea, GI effects) aligned with the incretin class. The outcome accelerates Lilly’s next‑generation obesity/diabetes strategy and intensifies competition among multi‑agonist programs from large drugmakers.